Your browser doesn't support javascript.
loading
Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma.
Hanania, Nicola A; Niven, Robert; Chanez, Pascal; Antoine, Deschildre; Pfister, Pascal; Garcia Conde, Lorena; Jaumont, Xavier.
Afiliação
  • Hanania NA; Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Niven R; Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
  • Chanez P; Clinique des Bronches, de l'Allergie et du Sommeil, Department of Respiratory Diseases, APHM, Aix-Marseille University, France.
  • Antoine D; CHU Lille, Université Nord de France, unité de pneumologie et allergologie pédiatriques, Hôpital Jeanne de Flandre, 59000 Lille, France.
  • Pfister P; Novartis Pharma AG, Basel, Switzerland.
  • Garcia Conde L; Novartis Pharma AG, Basel, Switzerland.
  • Jaumont X; Novartis Pharma AG, Basel, Switzerland.
World Allergy Organ J ; 15(10): 100695, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36254180
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article